Cardiff Oncology to Present at the Cowen 43rd Annual Health Care Conference

Rhea-AI Summary

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm focused on PLK1 inhibition for cancer therapies, announced its participation in the Cowen 43rd Annual Health Care Conference from March 6-8, 2023, at Boston Marriott Copley Place. Management will join a corporate panel discussion and conduct one-on-one investor meetings. The GI/GU Oncology panel discussion is scheduled for March 7 at 12:50 PM ET, with a webcast available for attendees. A replay will be accessible on the Cardiff Oncology website for 30 days post-conference.

For more details, visit Cardiff Oncology.

SAN DIEGO, Feb. 27, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers, today announced that company management will participate in a corporate panel discussion and 1x1 investor meetings at the Cowen 43^rd Annual Health Care Conference, which is taking place at the Boston Marriott Copley Place from March 6 – 8, 2023.

Details of the panel discussion can be found below.

GI/GU Oncology Panel Discussion

Date:	Tuesday, March 7, 2023
Time: Webcast Link:	12:50 PM ET Here

A replay of the panel discussion will be available by visiting the "Events" section of the Cardiff Oncology website and will be archived for 30 days following the completion of the conference.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com  

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-cowen-43rd-annual-health-care-conference-301755711.html

SOURCE Cardiff Oncology, Inc.

FAQ

What event is Cardiff Oncology participating in March 2023?

Cardiff Oncology is participating in the Cowen 43rd Annual Health Care Conference from March 6-8, 2023.

When is the panel discussion for Cardiff Oncology at the Cowen Conference?

The panel discussion is scheduled for March 7, 2023, at 12:50 PM ET.

Where is the Cowen 43rd Annual Health Care Conference held?

The conference is being held at the Boston Marriott Copley Place.

How can investors access Cardiff Oncology's panel discussion?

Investors can access the panel discussion via a webcast link provided by Cardiff Oncology.

Will there be a replay of Cardiff Oncology's panel discussion?

Yes, a replay will be available on Cardiff Oncology's website for 30 days after the conference.